Health  Vol.7 No.12 , December 2015
How Long to Treat with Bisphosphonates?
Abstract: Bisphosphonate class of drugs, the most commonly prescribed for the treatment of osteoporosis, is effective in preventing and treating bone loss and fractures. However, the treatment duration and the applicability of “drug holidays” for bisphosphonates need optimization in order to minimize long-term exposure. Drug holidays may prevent potential adverse events while still maintaining some degree of antifracture efficacy via residual antiresorptive activity by retained bisphosphonates. Patients receiving bisphosphonates, who are at low-moderate risk of fracture, are potential candidates for a drug holiday. However, for high-risk patients or patients with previous history of fragility fractures, the benefits of continuing bisphosphonate therapy considerably out-weigh their potential harm. Evidence-based guidelines regarding starting and stopping a drug holiday are not available; therefore, it is appropriate to monitor patients on a drug holiday to assess a declining antiresorptive effect. In case of a significant rise in bone turnover markers or significant decrease in bone mineral density, it may be time to restart therapy.
Cite this paper: Alshahrani, F. , Almalki, M. (2015) How Long to Treat with Bisphosphonates?. Health, 7, 1615-1621. doi: 10.4236/health.2015.712174.

[1]   Consensus Development Conference (1993) Diagnosis, Prophylaxis, and Treatment of Osteoporosis. The American Journal of Medicine, 94, 646-650.

[2]   Cooper, C., Atkinson, E.J., Jacobsen, S.J., O’Fallon, W.M. and Melton, L.J. (1993) Population-Based Study of Survival after Osteoporotic Fractures. American Journal of Epidemiology, 137, 1001-1005.

[3]   Black, D.M., Cummings, S.R., Karpf, D.B., et al. (1996) Fracture Intervention Trial Research Group. Randomised Trial of Effect of Alendronate on Risk of Fracture in Women with Existing Vertebral Fractures. The Lancet, 348, 1535-1541.

[4]   Cummings, S.R., Black, D.M., Thompson, D.E., et al. (1998) Effect of Alendronate on Risk of Fracture in Women with Low Bone Density but without Vertebral Fractures: Results from the Fracture Intervention Trial. JAMA, 280, 2077-2082.

[5]   Harris, S.T., Watts, N.B, Genant, H.K., et al. (1999) Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of Risedronate Treatment on Vertebral and Non-vertebral Fractures in Women with Postmenopausal Osteoporosis: A Randomized Controlled Trial. JAMA, 282, 1344-1352.

[6]   Russell, R.G., Muhlbauer, R.C., Bisaz, S., Williams, D.A. and Fleisch, H. (1970) The Influence of Pyrophosphate, Condensed Phosphates, Phosphonates and Other Phosphate Compounds on the Dissolution of Hydroxyapatite in Vitro and on Bone Resorption Induced by Parathyroid Hormone in Tissue Culture and in Thyroparathyroidectomised Rats. Calcified Tissue Research, 6, 183-196.

[7]   Russell, R.G., Watts, N.B., Ebetino, F.H. and Rogers, M.J. (2008) Mechanisms of Action of Bisphosphonates: Similarities and Differences and Their Potential Influence on Clinical Efficacy. Osteoporosis International, 19, 733-759.

[8]   Cremers, S.C., Pillai, G. and Papapoulos, S.E. (2005) Pharmacokinetics/Pharmacodynamics of Bisphosphonates: Use for Optimisation of Intermittent Therapy for Osteoporosis. Clinical Pharmacokinetics, 44, 551-570.

[9]   Miller, P.D., Bolognese, M.A., Lewiecki, E.M., McClung, M.R., Ding, B., Austin, M., et al. (2008) Effect of Denosumab on Bone Density and Turnover in Postmenopausal Women with Low Bone Mass after Long-Term Continued, Discontinued, and Restarting of Therapy: A Randomized Blinded Phase 2 Clinical Trial. Bone, 43, 222-229.

[10]   Drake, M., Clarke, B. and Khosla, S. (2008) Bisphosphonates: Mechanism of Action and Role in Clinical Practice. Mayo Clinic Proceedings, 83, 1032-1045.

[11]   Shane, E., Burr, D., Ebeling, P.R., Abrahamsen, B., Adler, R.A., Brown, T.D., et al. (2010) Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 25, 2267-2294.

[12]   Khosla, S., Burr, D., Cauley, J., Dempster, D.W., Ebeling, P.R., Felsen-berg, D., et al. (2007) Bisphosphonate-Asso- ciated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 22, 1479-1491.

[13]   Black, D.M., Schwartz, A.V., Ensrud, K.E., Cauley, J.A., Levis, S., Quandt, S.A., et al. (2006) Effects of Continuing or Stopping Alendronate after 5 Years of Treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A Randomized Trial. JAMA: The Journal of the American Medical Association, 296, 2927-2938.

[14]   Black, D.M., Reid, I.R., Boonen, S., Bucci-Rechtweg, C., Cauley, J.A., Cosman, F., et al. (2012) The Effect of 3 versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT). Journal of Bone and Mineral Research, 27, 243-254.

[15]   Watts, N.B., Chines, A., Olszynski, W.P., McKeever, C.D., McClung, M.R., Zhou, X. and Grauer, A. (2008) Fracture Risk Remains Reduced One Year after Discontinuation of Risedronate. Osteoporosis International, 19, 365-372.

[16]   Schwartz, A.V., Bauer, D.C., Cummings, S.R., Cauley, J.A., Ensrud, K.E., Palermo, L., et al. (2010) Efficacy of Continued Alendronate for Fractures in Women with and without Prevalent Vertebral Fracture: The FLEX Trial. Journal of Bone and Mineral Research, 25, 976-982.

[17]   Eastell, R., Hannon, R.A., Wenderoth, D., Rodriguez-Moreno, J. and Sawicki, A. (2011) Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover. The Journal of Clinical Endocrinology and Metabolism, 96, 3367-3373.

[18]   Seeman, E. (2009) To Stop or Not to Stop, That Is the Question. Osteoporosis International, 20, 187-195.

[19]   Park-Wyllie, L.Y., Mamdani, M.M., Juurlink, D.N., Hawker, G.A., Gunraj, N., Austin, P.C., et al. (2011) Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women. JAMA: The Journal of the American Medical Association, 305, 783-789.

[20]   Black, D.M., Bauer, D.C., Schwartz, A.V., Cummings, S.R. and Rosen, C.J. (2012) Continuing Bisphosphonate Treatment for Osteoporosis—For Whom and For How Long? The New England Journal of Medicine, 366, 2051-2053.

[21]   Papaioannou, A., Morin, S., Cheung, A.M., Atkinson, S., Brown, J.P., Feldman, S., et al. (2010) 2010 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada: Summary. Canadian Medical Association Journal, 182, 1864-1873.

[22]   Brown, J.P., Morin, S., Leslie, W., Papaioannou, A., Cheung, A.M., Davison, K.S., et al. (2014) Bisphosphonates for Treatment of Osteoporosis: Expected Benefits, Potential Harms, and Drug Holidays. Canadian Family Physician Medecin de Famille Canadien, 60, 324-333.

[23]   McClung, M., Harris, S.T., Miller, P.D., Bauer, D.C., Davison, K.S., Dian, L., et al. (2013) Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday. The American Journal of Medicine, 126, 13-20.

[24]   Hodgson, S.F., Watts, N.B., Bilezikian, J.P., et al. (2003) American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Prevention and Treatment of Postmenopausal Osteoporosis: 2001 Edition, with Selected Updates for 2003. Endocrine Practice, 9, 544-564.

[25]   American College of Obstetricians and Gynecologists (2004) Clinical Management Guidelines for Obstetrician Gynecologists. ACOG Practice Bulletin Number 50. Obstetrics & Gynecology, 103, 203-216.

[26]   Ott, S.M. (2011) What Is the Optimal Duration of Bisphosphonate Therapy? Cleveland Clinic Journal of Medicine, 78, 619-630.

[27]   Bonnick, S.L. and Shulman, L. (2006) Monitoring Osteoporosis Therapy: Bone Mineral Density, Bone Turnover Markers, or Both? The American Journal of Medicine, 119, S25-S31.